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Summary This study evaluated the impact of province-wide treatment guidelines on consistency of adjuvant therapy for node-negative breast
cancer. A retrospective population-based cohort study was conducted in the Canadian provinces of British Columbia, which has province-
wide guidelines, and Ontario, which does not. All eligible 1991 incident cases of node-negative breast cancer in British Columbia (n = 942)
and a similar number of randomly selected 1991 incident cases in Ontario (n = 938) were reviewed. Consistency of adjuvant therapy received
was evaluated by stratifying cases into discrete diagnostic groups using several grouping systems, and by then comparing the distribution of
treatments received within each diagnostic group in the two provinces. Recursive partitioning was also performed. We observed that patterns
of pathology reporting were consistent with awareness of the factors used in the British Columbia guidelines to define indications for adjuvant
therapy. Consistency of care was greater in British Columbia than in Ontario by all diagnostic grouping systems and by recursive partitioning
(P < 0.001), and the observed patterns in British Columbia corresponded to the British Columbia guidelines. We conclude that population-
based treatment guidelines can play a role in promoting consistent patterns of adjuvant therapy for women with node-negative breast cancer.
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Treatment guidelines have been developed for a wide variety of
diseases, including breast cancer (Audet et al, 1990; Committee to
Advise the Public Health Service on Clinical Practice Guidelines,
1990; Glick et al, 1993). Although the traditional objective of
treatment guidelines has been to improve disease-related outcomes
such as time to recurrence and survival, more recently treatment
guidelines have been recommended because of their potential to
influence other aspects of care (Kanouse et al, 1988; Kelly et al,
1992; Shapiro et al, 1993). For example, even in scenarios in
which several treatment strategies produce equivalent outcomes or
in which survival benefits are modest, treatment guidelines may
ensure accurate interpretation of prognostic factors, standardize
treatment options presented to patients, limit the use oftoxic treat-
ment when risk greatly outweighs benefit and control costs.
Guidelines can potentially improve care by providing health
care practitioners with indications for, and details of, treatment to
be offered to patients. Care ofpatients is only improved, however,
ifthe guidelines are followed (that is observed patterns of care are
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consistent within similar groups of patients and they resemble the
treatment guidelines) and if they are correct (that is appropriate
care is recommended by the guidelines).
Adjuvant systemic therapy has been used increasingly in
women with axillary node-negative breast cancer (NNBC) to
delay or prevent recurrence (Henderson, 1991). Because benefits
have been modest with respect to both recurrence rates and
survival, and both chemotherapy and tamoxifen have associated
toxicities, it has been suggested that adjuvant systemic therapy be
restricted to women with NNBC who, by virtue ofthe presence of
adverse clinical and pathological features, have a moderate orhigh
risk of recurrence (Scottish Cancer Trials Office, 1987; CRC
Adjuvant Breast Trial Working Party, 1988; Fisher et al, 1988,
1989a,b; Ludwig Breast Cancer Study Group, 1989; McGuire,
1989; Mansour et al, 1989; McGuire et al, 1992; Early Breast
Cancer Trialists' Collaborative Group, 1992). Several treatment
guidelines for adjuvant systemic therapy for NNBC have been
developed and distributed, but the actual impact of these guide-
lines on consistency ofcare is uncertain. In the few studies to date,
the impact oftreatment guidelines on patterns ofbreast cancer care
has been modest, if detectable at all (McPhee et al, 1986; Ford et
al, 1987; Gregorio et al, 1990; Grilli et al, 1991; McCarthy and
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Table 1 Exclusion criteria for node-negative breast cancer cohorts in British Columbia and Ontario, 1991
Criteria for exclusion British Columbia Ontario
No. % No. %
1991 Registered cases 2317 5760
Duplicate numbers 1 0.0 7 0.1
Age over 90 32 1.4 83 1.4
Diagnosis by death certificate only/death within 30 days of diagnosis 32 1.4 112 1.9
Non-epithelial malignancies/non-malignancies 27 1.2 23 0.4
Previous invasive cancer or previous breast in situ 207 8.9 254 4.4
Random selectiona 2917
Cancer centre/hospital not participating 275 8.6a
Synchronous invasive cancer/in situ breast 86 3.7 28 o.9a
In situ breastborderline malignancy 221 9.5 30 o.9a
Staging
Chest wall extension or metastatic 105 4.5 149 4.7a
Node-positive 534 23.1 670 21.1a
Nodal status not known 120 5.2 242 7.6a
Treatment out of province 10 0.4 5 0.2a
Chart could not be located/sex or cancer site/not diagnosed in 1991 0 0.0 27 0.8a
Total excluded 1375 4822
Total in study 942 938
Local regional therapy trial 7 0.7 0
aThe sampling fraction in Ontario is 55% of cases eligible at time of random selection. Remaining percentages in table for Ontario are corrected for the sampling
fraction (i.e. represent estimated proportion of all registered cases).
Bore, 1991). The majority ofthese reports evaluated the influence
of guidelines at a circumscribed level such as the hospital or
university; very few have examined the impact oftreatment guide-
lines at the level of the entire population. Most of these studies
focused on physician compliance with the guidelines. None ofthe
studies compared patterns of care in settings with guidelines and
those without them, and therefore it has been impossible to distin-
guish true effects of the guidelines from physician awareness of
medical knowledge. One time-series analysis suggested that the
1988 National Cancer Institute Clinical Alert, which informed
physicians ofthe results ofadjuvant chemotherapy trials in women
with NNBC, and was accompanied by considerable media atten-
tion, led to increases in chemotherapy utilization that were tran-
sient in some patient subsets but sustained in others (Johnson et al,
1994). Another study found variable responses to the Clinical
Alert: in a single large metropolitan area, the major university
hospital increased its use ofadjuvant chemotherapy for all subsets
ofNNBC following the Clinical Alert, whereas the major commu-
nity hospital did so only for some subsets (Studnicki et al, 1993).
In Canada, health care is under provincial jurisdiction and the
degree to which practice guidelines have been developed is varied
(Olivotto et al, 1994; Browman et al, 1995). In British Columbia,
province-wide guidelines for cancer care have been in place since
the mid-1970s (Olivotto et al, 1994). The guidelines are updated
periodically by a multidisciplinary group comprising both acad-
emic and community physicians and are widely disseminated to
all relevant physicians, surgeons and hospitals throughout the
province. In contrast, in Ontario, no provincial guidelines existed
before 1994, but they are now under development (Browman et al,
1995). Instead, some individual cancer treatment centres and
hospitals have developed local guidelines, with variable dissemi-
nation to referring surgeons and surrounding community hospitals.
This study compares adjuvant systemic treatments received by
women with NNBC in British Columbia and Ontario in 1991. The
existence ofthese two cancer care models has allowed us to assess
the impact of province-wide treatment guidelines on adjuvant
systemic therapy for NNBC at a population-based level. For this
study, we did not attempt to determine whether the British
Columbia guidelines were correct and we did not specifically
assess reasons for non-compliance with these guidelines.
Compliance in British Columbia is the subject of another report
(Olivotto et al, 1997). Rather, we restricted our attention to assess-
ment ofthe association between guidelines and consistency ofcare
in each province. We hypothesized that care would be more
consistent (defined as more homogeneous care within specified
diagnostic subgroups) in British Columbia than in Ontario, and
that this difference would be associated with the presence of
province-wide treatment guidelines in British Columbia.
METHODS
Study subjects
A retrospective population-based cohort study was conducted by
identifying incident cases of node-negative breast cancer diag-
nosed in 1991 in each province. The provincial cancer registries,
which have been documented to have high levels ofcompleteness
(McBride and Donaldson, 1987; Robles et al, 1988), were used to
select cases. In British Columbia, the cohort consisted of all
eligible cases. In Ontario, because of its larger population and
substantially larger number of cases diagnosed in the same time
period, a random sample was selected to provide an equivalent
number ofcases.
Exclusion criteria included age greater than 90 years at time of
diagnosis, diagnosis by death certificate only, death within 30 days
of diagnosis, clinical stage III or IV disease, in situ disease, non-
epithelial malignancies and any previous invasive cancer (except
non-melanomatous skin cancers) or history of breast carcinoma
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Table 2 Provincial adjuvant systemic therapy guidelines for node-negative breast cancer in effect in British
Columbia in 1991
Diagnostic grouping 1991 Adjuvant systemic therapy guideline
< 50 years low risk No adjuvant therapy
< 50 years high riska Chemotherapy
50-65 years low risk No adjuvant therapy
50-65 years high risk ER positive Tamoxifen and chemotherapy ortamoxifen
50-65 years high risk ER negative Chemotherapy
> 65 years low risk No adjuvant therapy
> 65 years high risk ER positive Tamoxifen
> 65 years high risk ER negative No adjuvant therapy
aHigh risk, presence of cancer invasion of lymphatics, blood vessels or nerves (LVN), or tumour > 2 cm if ER
negative. Note: if ER unknown, assumed to be positive; if no comment on lymphatic, vascular or neural
invasion, assumed to be absent.
in situ. Patients with pathological node-positive or nodal status
unknown disease were excluded. Patients entered on clinical trials
of systemic therapy were excluded from all analyses which used
that therapy as the outcome measure. Table 1 shows the reasons for
exclusion and the final cohort assembly in the two provinces.
Data collection
Common data elements were identified a priori, encompassing
patient demographic features, characteristics of the primary
tumour, physicians and hospitals, and treatment received. For
cases-in which pathology was reviewed at the cancer centre, these
results took precedence over original reports. All information
already within the cancer registries in electronic format was
retrieved first, followed by examination of centrally stored docu-
ments (e.g. pathology reports) and other databases (e.g. physician
billings, drug data). Next, trained abstractors completed informa-
tion by chart review at cancer centres and larger hospitals. Finally,
outstanding information was sought by writing to hospitals and to
responsible physicians. Physician and hospital characteristics were
obtained from the 1991 Canadian Medical Directory and 1991
Canadian Hospital Association Directory 1991-1992 (Canadian
Hospital Association, 1991). Patient socioeconomic status was
imputed using postal code geography at the forward sortation area
(FSA) level (Wilkins, 1993). For each FSA (which has a popula-
tion of approximately 10 000) the median family income was
obtained from the 1991 census of the population (Statistics
Canada, 1992).
Coding and abstraction guidelines were established before the
study began and the data abstractors were trained jointly. They
periodically exchanged materials for comparison purposes and all
difficult cases were reviewed in conjunction with the investigators.
Patient, physician and hospital anonymity were preserved. The
study was approved by all relevant institutional ethics committees.
DATA ANALYSIS
Each province conducted initial analyses independently to assess
the completeness and quality of data and to generate descriptive
statistics. The final data sets were merged and key variables in the
two provinces were compared using chi-squared tests for categor-
ical data and t-tests for continuous variables. Chi-squared tests
were used to test the association between independent variables
and the use of a specific therapy within each province. The
Mantel-Haenszel test of heterogeneity was used to assess the
significance of the interaction between each independent variable
and the province in order to determine ifindependent variables had
different influences on the likelihood ofuse ofa specific therapy in
each province. A non-significant Mantel-Haenszel test of hetero-
geneity would result when the independent variable was associated
with treatment in a similar fashion in the two provinces.
To compare consistency of adjuvant systemic therapy received
by women in the two provinces, cases were first stratified into
eight discrete diagnostic groupings as defined in the British
Columbia guidelines on the basis ofpatient age, risk ofmetastases
and oestrogen receptor (ER) status (Table 2). The distribution of
treatments received within each diagnostic group, including
chemotherapy, tamoxifen, both chemotherapy and tamoxifen, or
neither treatment, were compared in the two provinces. Cases in
which missing information on risk factors precluded stratification
or in which treatment was unknown were omitted from this and
subsequent analyses examining consistency of treatment. In addi-
tion to stratification based on the British Columbia guidelines
alternative systems ofdiagnostic group development were applied.
Initially, the basic structure ofthe British Columbia guidelines was
preserved but the criteria for assigning risk were altered, based on
factors that may have been in use for selection of patients for
systemic therapy, such as the substitution of tumour grade for
invasion of lymphatics, blood vessels or nerves (LVN).
As the British Columbia guidelines impose certain assumptions
about the structure of the stratification scheme, recursive parti-
tioning was also used to assess the factors associated with adjuvant
systemic therapy in each provincial cohort (Breiman et al, 1994).
This is an assumption-free statistical approach that partitions the
data into groups to ascertain the relationships between independent
variables and the dependent variable, in this case the treatment
received. Factors such as age and tumour size were entered as
continuous variables without specification ofcut-offvalues.
'Consistency' was defined in terms ofthe homogeneity oftreat-
ments received within each diagnostic stratum. The calculation of
consistency scores and the statistical test for comparison between
scores is shown in Appendix 1. A score of 1 means that all subjects
received a single treatment within each stratum. A score of zero
occurs when equal numbers of subjects in each stratum receive
each treatment, a result that suggests that the stratification scheme
under scrutiny is not a good predictor of who receives a particular
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Table 3 Patient and tumour characteristics by province
British Columbia Ontario
n = 942 % Per cent known n = 938 % Per cent known Inter-provinical
comparison (P)
Age (years)
< 50 196 20.8 234 25.0
50-65 318 33.8 358 38.2
> 65 428 45.4 346 36.9 < 0.001
Rural residence 145 15.4 138 14.7 0.680
Median family income in area of residence
>$50 000 246 26.1 318 33.9 < 0.001
Referred to cancer centre 664 70.5 668 71.2 0.729
Size
< 2 cm 585 62.1 62.3 547 58.3
2-4 cm 315 33.4 33.5 344 36.7
> 4 cm 39 4.1 4.1 37 3.9
Unreported 3 0.3 - 10 1.1 0.095
Grade
Well 106 11.3 13.0 102 10.9 17.1
Moderate 391 41.5 48.0 308 32.8 51.7
Poor 317 33.7 38.9 186 19.8 31.2 0.005
Unreported 128 13.6 - 342 36.5 -
LVN invasion
Absent 648 68.8 76.4 232 24.7 68.0
Present 200 21.2 23.5 109 11.6 31.9 0.003
Unreported 94 10.0 - 597 63.7 -
Oestrogen receptor status
Positive 569 60.4 79.3 597 63.7 76.7
Negative 148 15.7 20.6 181 19.3 23.2
Unreported 225 23.9 - 160 17.1 - < 0.001
Progesterone receptor status
Positive 366 38.9 64.2 506 53.9 65.1
Negative 204 21.7 35.7 271 28.9 34.8 < 0.001
Unreported 372 39.5 - 161 17.2 -
treatment. Note that the consistency statistic does not assume
which is the 'correct' or 'appropriate' treatment for any stratum.
RESULTS
Patient demographics, tumour and physician
characteristics
The final cohorts consisted of 942 cases in British Columbia and
938 cases in Ontario. As shown in Table 3, the two groups are
comparable with respect to most patient demographics, except for
the age distribution, which was somewhat older in the British
Columbia cohort, and the income distribution, in which a slightly
greater proportion of Ontario cases resided in areas with higher
income levels. Tumour characteristics such as size, and, when
reported, grade, ER and progesterone receptor (PgR) status were
comparable in the two provinces. A comment regarding the pres-
ence or absence of LVN was made on 90.0% ofpathology reports
in British Columbia and 36.3% in Ontario (P < 0.001). Nearly
80% of women in both provinces were referred to medical or
radiation oncologists after surgery.
Adjuvant systemic therapy
Ten cases in British Columbia and five cases in Ontario were
entered on clinical trials of adjuvant systemic therapy and are not
included in any subsequent analyses examining adjuvant systemic
therapy. In Ontario, it was not possible to ascertain whether
chemotherapy or tamoxifen were recommended for one and 22
cases respectively. For the remaining 932 British Columbia cases
and 911 Ontario cases, 33.9% in Ontario received some form of
treatment compared with 25.9% in British Columbia (P < 0.001).
Chemotherapy, with or without tamoxifen, was used in 9.6% of
cases in British Columbia and 7.1% in Ontario (P = 0.054), whereas
tamoxifen, with or without chemotherapy, was used in 28.4% of
cases in Ontario and 17.5% in British Columbia (P < 0.001).
The factors associated with the use ofchemotherapy are shown in
Table 4. Increased use ofchemotherapy was associated with younger
age, larger tumour size, poor tumour grade and negative ER status in
both provinces. However, in British Columbia, age < 50 years and
LVN status (present or absent) was associated with chemotherapy
more strongly than in Ontario. The interprovincial differences were
statistically significant for LVN (P = 0.003) but not for age < 50
(P = 0.376). These factors accounted for almost all of the observed
difference in chemotherapy utilization in the two provinces.
Table 5 describes the features associated with the use oftamox-
ifen. In both provinces, similar trends were observed for more
frequent use oftamoxifen in the post-menopausal population, and
with increasing tumour size, presence of LVN and, to a lesser
extent, with worsening tumour grade. Tamoxifen was used much
more frequently in ER-positive than in ER-negative strata. As was
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Table 4 Association of patient and tumour factors with use of chemotherapya in British Columbia and Ontario
British Columbia use of chemotherapy Ontario use of chemotherapy
No. % No. % Interprovincial Mantel-Haenszel
test for heterogeneity (P)
Overall rate of chemotherapy (+/-) Tamoxifen 89/932 9.6 66/932 7.1
Age (years)
< 50 75/189 39.7 53/230 23.0
50-65 13/318 4.1 12/357 3.4
> 65 1/425 0.2b 1/345 0.3b 0.374
Median family income in area of residence
< $35 000 14/122 11.5 7/123 5.7
$35 001-$50 000 50/570 8.8 32/495 6.5
>$50 000 25/240 10.4 27/314 8.6 0.616
Tumour size
< 2 cm 29/577 5.0 21/543 3.9
2-4 cm 53/314 16.9 34/342 9.9
>4cm 7/38 18.4 9/37 24.3
Unreported 0/3 0.Ob 2/10 20.0b 0.432
Tumour grade
Well 3/103 2.9 1/102 1.0
Moderate 21/388 5.4 16/304 5.3
Poor 61/313 19.5 34/184 18.5
Unreported 4/128 3.1b 15/342 4.4b 0.723
LVN invasion
Absent 39/641 6.1 17/229 7.4
Present 49/198 24.8 11/109 10.1
Unreported 1/93 1.1b 38/594 6.4 0.003
Oestrogen receptor
Positive 33/565 5.8 20/593 3.4
Negative 42/146 28.8 39/179 21.8
Unreported 14/221 6.3b 7/160 4.4b 0.863
aExcludes cases on clinical trials of adjuvant systemic therapy or those in whom chemotherapy status was unknown. bIntraprovincial chi square P< 0.001. All
other categories P > 0.2.
observed with the use of chemotherapy, LVN status (present or
absent) correlated with treatment more strongly in British
Columbia than in Ontario (P < 0.0001). The difference in tamox-
ifen use rates is accounted forby the less frequent use oftamoxifen
in British Columbia women younger than age 50 years (P = 0.028)
or those with tumours less than 2 cm (P = 0.254). In Ontario, a
trend to greater use of tamoxifen was seen in association with
residence in areas of higher family income (P < 0.001), whereas
no such trend was observed in British Columbia.
Comparison of consistency of adjuvant systemic
therapy in British Columbia and Ontario
Table 6 compares the distribution oftreatments received by British
Columbia and Ontario cases for each of the eight diagnostic
groups specified in the British Columbia guidelines. In British
Columbia, in five of the eight diagnostic groups, 78% or more of
the women in each stratum received the guideline-recommended
treatment. The proportion of women in the other three diagnostic
groups receiving treatment recommended by the guidelines ranged
from 19.1% to 68.9%. Treatment received in Ontario did not corre-
spond closely to the British Columbia guidelines and a broader
distribution of treatment was observed in almost all diagnostic
groups. Overall, as shown in Table 7, when the cohorts were clas-
sified by the British Columbia guidelines, consistency scores were
higher in British Columbia than in Ontario (classification system
1, P <0.001). When Ontario and British Columbia cases were both
reclassified using criteria derived from practitioners in Ontario, the
distribution of treatments received in Ontario was still broader
than the distribution of treatments received in British Columbia
(Table 7, classification systems 2-5, P < 0.001 for all systems).
Recursive partitioning was performed for several outcome vari-
ables: chemotherapy vs no chemotherapy, tamoxifen vs no tamox-
ifen, any systemic treatment vs no systemic treatment, and the four
category combination of no treatment, chemotherapy, tamoxifen
and both. In each case a stratification scheme based on a hierarchy
of tumour and patient characteristics that predicted use of treat-
ment was developed for the Ontario cohort. The resulting best-fit
Ontario model included ER status, age and grade. However, when
each ofthese schemes was applied to the British Columbia data the
consistency scores were always higher in British Columbia than in
Ontario. When the British Columbia data was subjected to the
recursive partitioning algorithm the resulting scheme, which
included LVN, ER status, tumour size and age, corresponded
closely with the British Columbia guidelines (Table 7, classifica-
tion system 6, P < 0.001).
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Table 5 Association of patient and tumour factors with use of tamoxifena in British Columbia and Ontario
British Columbia use of tamoxifen Ontario use of tamoxifen
No. % No. % Interprovincial Mantel-Haenszel
test for heterogeneity (P)
Overall rate of tamoxifen (+/- chemotherapy) 163/932 17.5 259/911 28.4
Age (years)
< 50 7/189 3.7 40/226 17.7
50-65 67/318 21.1 115/346 33.2
> 65 89/425 20.9b 104/339 30.7b 0.028
Median family income in area of residence
< $35 000 24/122 19.7 24/121 19.8
$35 001-$50 000 103/570 18.1 129/484 26.7
> $50 000 36/240 15.0 106/306 34.6c 0.011
Tumour size
< 2 cm 74/577 12.8 134/534 25.1
2-4 cm 78/314 24.8 109/331 32.9
>4cm 10/38 26.3 14/36 38.9
Unreported 1/3 33.3b 2/10 20.0d 0.254
Tumour grade
Well 14/103 13.6 23/99 23.2
Moderate 63/388 16.2 97/303 32.0
Poor 58/313 18.5 60/182 33.0
Unreported 28/128 21.9 79/327 24.2e 0.098
LVN invasion
Absent 61/641 9.5 57/224 25.5
Present 90/198 45.5 45/108 41.7
Unreported 12/93 12.9b 157/579 27.1' < 0.0001
Oestrogen receptor
Positive 127/565 22.5 213/585 36.4
Negative 13/146 8.9 22/174 12.6
Unreported 23/221 10.4b 24/152 15.8b 0.674
aExcludes cases on clinical trials of adjuvant systemic therapy or those in whom Tamoxifen treatment status was unknown. Intraprovincial chi square:
bp< 0.001; cp = 0.004; dp = 0.037; ep = 0.046; 'P = 0.005. All other categories P> 0.2
Table 6 Proportion of patients who received adjuvant systemic therapy in each diagnostic grouping as per British Columbia guidelines
British Columbia Ontario
Total No Adjuvant Tamoxifen Tamoxifen Total No Adjuvant Tamoxifen Tamoxifen
adjuvant chemotherapy and adjuvant chemotherapy and
therapy chemotherapy therapy chemotherapy
n % % % % n % % % %
< 50 years low risk 119 84.9 12.6 - 2.5 167 70.1 12.0 14.4 3.6
<50 years high risk 70 15.7 78.6 2.9 2.9 57 40.4 42.1 15.8 1.8
50-65 years low risk 236 90.3 0.9 8.5 0.4 280 67.9 0.7 30.0 1.4
50-65 years high risk ER positive 61 29.5 1.6 62.3 6.6 31 38.7 - 58.1 3.2
50-65 years high risk ER negative 21 61.9 19.1 14.3 4.8 35 71.4 5.7 17.1 5.7
> 65 years low risk 327 85.9 0.3 13.8 - 289 69.6 - 30.1 0.4
> 65 years high risk ER positive 69 43.5 - 56.5 - 33 60.6 - 39.4 -
> 65 years high risk ER negative 28 82.1 - 17.9 - 16 81.3 - 18.8
Numbers in bold represent the treatment by the British Columbia guidelines.
DISCUSSION
In this study, we observed greaterconsistency in the use ofadjuvant
systemic therapy in British Columbia than in Ontario, and the
observed pattems in British Columbia corresponded to the British
Columbiaguidelines. As summarized in Table 7, higherconsistency
scores were observed in British Columbia regardless of the diag-
nostic grouping system used for analysis, and the effect persisted
even in the assumption-free recursivepartitioning procedure.
In three of the eight diagnostic groups defined by the British
Columbia guidelines, recommended treatment was received by
only 19.1-68.9% ofwomen. Anotherreport examines in detail the
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Table 7 Consistency scorea for different methods of diagnostic group development
Differences from British Columbia classification British Columbia Ontario Z-statisticb
Group 1 None 0.758 0.514 9.36
Group 2 High risk, presence of 'poor' grade or presence of LVN invasion or
tumour > 2cm if ER negative 0.670 0.509 5.10
If oestrogen receptors 'unknown' is assumed to be positive
Group 3 High risk defined as in group 2 0.668 0.506 5.12
Risk is 'unknown' if oestrogen receptor is unknown.
Group 4 High risk, presence of 'poor' grade or tumour > 2 cm if ER negative.
Presence or absence of LVN invasion not considered 0.657 0.513 4.39
If oestrogen receptor 'unknown' is assumed to be positive.
Group 5 High risk is defined as in group 4 0.658 0.511 4.47
Risk is 'unknown' if oestrogen receptor unknown
Group 6 Recursive partitioning model 0.676 0.573 3.73
alf a grouping gives perfect classification, then the statistic is 1. If equal proportions of the patients in each group get the four treatments, that statistic is zero.
bFor the comparison between the two provinces, all P-values are < 0.001.
reasons for less than optimal compliance with the British
Columbia guidelines for these groups of women (Olivotto et al,
1997). In Ontario, however, only 5.7-61.3% of similar women
received treatment as recommended by the British Columbia
guidelines, supporting the suggestion that in British Columbia,
treatment guidelines were incorporated into therapeutic decisions,
at least by some physicians.
We also observed patterns of pathology reporting in British
Columbia that suggest that pathologists were aware of the factors
that clinicians were using for assessment of the risk of metastatic
potential according to the British Columbia guidelines. This is
most evident for reporting ofLVN, in which a comment regarding
LVN was made in 90% of cases. In contrast, in Ontario, where,
in 1991, LVN was not commonly used as a prognostic factor,
LVN was commented upon in only 36.3% of cases. Thus, it
appears that the British Columbia guidelines led to pathology
reports that included those factors relevant to the treatment
decision. The standardized format for pathology reporting in
the cancer centres may have increased awareness in the commu-
nity pathology setting of these factors required for treatment
recommendation.
We also observed a stronger correlation of both LVN status and
age with recommendations for both chemotherapy and tamoxifen
in British Columbia than in Ontario (Tables 4 and 5), supporting
the view that physicians were aware of and using the British
Columbia guidelines in British Columbia. The associations
between all other independent variables and tamoxifen were not
statistically different in the two provinces, with the exception of
residence in areas of higher median family income for a recom-
mendation for tamoxifen.
The observed trend toward increased use of adjuvant systemic
therapy in women residing in areas ofhigher socioeconomic status
in the Ontario cohort must be interpreted with caution as the vari-
able represents median family income of the area of residence
rather than actual family income ofthe cases. However, with these
limitations in mind, there did appear to be a trend to greater use of
tamoxifen in women residing in areas of higher socioeconomic
status in Ontario. Whether this is due to differences in treatments
offered or in patient expectations oftreatment cannot be answered
by this study. However, the lack of a similar trend in the British
Columbia cohort suggests that provincial treatment guidelines
may have played a role in limiting the influence of socioeconomic
status on treatments recommended in that province.
The evaluation ofthe impact oftreatment guidelines on patterns
of care is problematic. Many of the studies published to date were
not truly population based (McPhee et al, 1986; McCarthy and
Bore, 1991; Studnicki et al, 1993; Grimshaw et al, 1995). Most
studies did not compare practice patterns in centres with and
without guidelines and therefore, even if guideline compliance
was observed, it has not been possible to distinguish between true
effects oftreatment guidelines and general physician knowledge of
good medical practice that may be adopted irrespective of the
existence oftreatment guidelines. Similarly, these studies have not
been able to determine whether consistency of care, as measured
by the homogeneity of treatments received, is improved by the
presence ofguidelines.
The strengths of the current study include the use of a popula-
tion-based cohort rather than a selected population referred to
cancer centres and the retrieval of data from actual source docu-
ments rather than solely from administrative data sets. Both of
these aspects should improve the generalizability and validity of
our results. Our approach also allows a comparison ofconsistency
of care in the two provinces without making any assumptions
about whether the British Columbia treatment guidelines are
correct. Another strength is the comparison of patterns of care in
two provinces that are similar in many respects. For example,
British Columbia and Ontario both have populations of similar
socioeconomic makeup (Statistics Canada, 1992) that reside
largely in urban areas, universal health care insurance, similar
medical training programmes and similar cancer care systems
consisting of regional cancer centres that are responsible for the
delivery of all radiation therapy.
Limitations ofour study include possible undetected differences
in data quality in the two provinces, some missing data on
chemotherapy and tamoxifen use in Ontario, a lack of detailed
information on co-morbidity that may have influenced treatment
decisions and patient preferences for treatment. Although most of
the tumour, patient and physician characteristics were comparable
in the two provinces, the average age of the British Columbia
cohort was somewhat older than the Ontario cohort. This may be
explained partly by the older average age in British Columbia
(Statistics Canada, 1992) and the higher incidence ofbreast cancer
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in British Columbia (National Cancer Institute of Canada, 1995),
but may also relate to differential selection ofpatients for axillary
dissection. Even after stratification by age, however, differences in
consistency ofcare persisted in the two provinces. Another limita-
tion of our study is the inability to totally dissect the impact of
treatment guidelines from small differences in the organization of
the medical care systems. Although British Columbia and Ontario
provide similar per capita cancer services, British Columbia,
which had a 1991 population of 3.3 million, had one cancer care
agency with two cancer centres, whereas Ontario, with a 1991
population of 10 million, had two cancer care organizations that
operated nine regional cancer centres. In British Columbia,
although there are no restrictions on drug prescriptions, the British
Columbia Cancer Agency controls a provincial centralized formu-
lary for anti-cancer drugs, and reimbursement occurs only after the
patient is registered with, but not necessarily seen at, the British
Columbia Cancer Agency. No centralized formulary for cancer
drugs exists in Ontario. The extent to which these differences may
have contributed to our observations is unknown.
Our study did not examine appropriateness or quality of care
and is not intended to comment on these aspects in either province,
nor is this an assessment of whether the guidelines in effect in
British Columbia in 1991 were correct. Our results do, however,
support the view that, once optimal adjuvant systemic therapy is
defined, treatment guidelines can play a role in promoting consis-
tent patterns of care and reducing the impact ofextraneous factors
such as socioeconomic status.
Although one goal oftreatment guidelines is the timely dissem-
ination of new information to treating physicians, paradoxically,
strict adherence to treatment guidelines may actually impede the
rapid introduction of newly reported therapies into clinical prac-
tice. For example, in this 1991 cohort, tamoxifen was used more
commonly, albeit inconsistently, in Ontario than in British
Columbia for women with smaller ER-positive tumours, and there
has subsequently been an increasing tendency to prescribe tamox-
ifen in this setting (Glick et al, 1993). Thus, although guidelines
appear to improve consistency of care, their role in improving
quality of care is highly dependent on frequent review and incor-
poration ofnew research findings into the guidelines, as well as on
appropriate and rapid dissemination of the updated guidelines
(Mittman et al, 1992; Browman et al, 1995; Grimshaw et al, 1995).
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APPENDIX 1: CALCULATION OF THE
CONSISTENCY SCORE AND ITS SIGNIFICANCE
A consistency score was developed to assess the homogeneity of
treatments across diagnostic strata. For each diagnostic grouping
the proportion of cases receiving the most frequently used treat-
ment was calculated. These quantities were summed across all the
strata within a province, weighting by the proportion ofsubjects in
that stratum in each province. The resulting quantity was then
transformed to yield a consistency score that could range between
zero and one in each province. The consistency score (C) is calcu-
lated according to the following formula:
C t [ wi] P 1
where kis the number ofdiagnostic strata, tthe number ofpossible
treatments, pi is the proportion ofsubjects within a strata receiving
the most frequently used treatment andw, is a weighting factor that
sums to 1. We used the proportion of subjects in each strata as the
weighting factor.
A test for comparing consistency scores was constructed by
considering the number receiving the most frequent treatment as a
binary variable in each treatment stratum. It was assumed that the
underlying frequency of the most commonly given treatment was
sufficiently greater than the underlying frequency of the other
treatments so that the distribution of the observed maximum was
well approximated by a binomial variable in each stratum. A
significance test for differences in the statistic C between the
provinces was constructed using its approximate asymptomatic
normality where the variance was calculated in the usual way for a
binomial distribution.
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